✓ Translated by DotMD AI Clinical Council Source: Hypertension research : official journal of the Japanese Society of Hypertension • Meta-Analysis

Verify Primary Source: NIH PubMed PMID #23945962 ↗

Meta-Analysis: A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure (N = 2,409)

Original Paper Title: “A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure”

Elena Rostova (AI Quant) Rigor Score

94 / 100

Sample Size (Participants)

N = 2,409

Evidence Classification

Meta-Analysis

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Pooled analysis suggested significant reductions in all of 24-h (MD of systolic/diastolic BP, -2.09/-1.57 mm Hg; 95% CI, -3.39/-2.32 to -0.79/-0.82 mm Hg), last 6-h (-2.96/-2.15 mm Hg; -3.80/-2.72 to -2.13/-1.59 mm Hg), morning (-2.71/-2.37 mm Hg; -3.73/-3.33 to -1.69/-1.41 mm Hg), daytime (-1.74/-1.73 mm Hg; -3.27/-2.84 to -0.20/-0.62 mm.
Study Design & Sample: Meta-Analysis published in Hypertension research : official journal of the Japanese Society of Hypertension (N = 2409 human participants).
Biostatistical Rigor Score: 94/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Hypertension research : official journal of the Japanese Society of Hypertension (2013), this meta-analysis evaluating 2,409 human participants investigated: A previous meta-analysis of a few randomized controlled trials (RCTs) suggests a significant reduction in ambulatory blood pressure (BP) with telmisartan as compared with losartan monotherapy. Key clinical takeaway: Pooled analysis suggested significant reductions in all of 24-h (MD of systolic/diastolic BP, -2.09/-1.57 mm Hg; 95% CI, -3.39/-2.32 to -0.79/-0.82 mm Hg), last 6-h (-2.96/-2.15 mm Hg; -3.80/-2.72 to -2.13/-1.59 mm Hg), morning (-2.71/-2.37 mm Hg; -3.73/-3.33 to -1.69/-1.41 mm Hg),...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Hypertension research : official journal of the Japanese Society of Hypertension, 2013-11-15; N = 2409; Rigor 94/100): Pooled analysis suggested significant reductions in all of 24-h (MD of systolic/diastolic BP, -2.09/-1.57 mm Hg; 95% CI, -3.39/-2.32 to -0.79/-0.82 mm Hg), last 6-h (-2.96/-2.15 mm Hg; -3.80/-2.72 to -2.13/-1.59 mm Hg), morning (-2.71/-2.37 mm Hg; -3.73/-3.33 to -1.69/-1.41 mm Hg), daytime (-1.74/-1.73 mm Hg; -3.27/-2.84 to -0.20/-0.62 mm.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: telmisartan → Rx: losartan-potassium → Rx: losartan-potassium-and-hydrochlorothiazide → Rx: pressure-pain-and-mucus-acetaminophen-guaifenesin-phenylephrine-hcl → Condition: embolism-fat → Condition: embolism-amniotic-fluid →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 23945962: Meta-Analysis: A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure (N = 2,409)

3 of 3 Free Questions Remaining